Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue
Aptus Pharma Ltd 路 Others (Uncategorized) 路 31 Oct 2026, 1:01 am
Aptus Pharma Receives In-Principle BSE Approval for Preferential Issue Aptus Pharma Ltd. received in-principle approval from BSE Ltd. on 30th Oct'26 under Regulation 28(1) of SEBI LODR Regulations for a proposed preferential issue. The approval covers the issuance of 15,99,270 equity shares (face value of Rs. 10 each) at a minimum price of Rs. 280 per share to promoters and non-promoters, aggregating to at least Rs. 44.78 cr. The issue was previously approved by shareholders at the AGM on 14th Sep'26. Final listing remains subject to regulatory compliance and post-allotment filings.
Original exchange filing (PDF)
More announcements from Aptus Pharma Ltd
- Outcome of Board Meeting - Allotment of Equity Shares on Preferential Basis under Regulation 30 of SEBI LODR Regulations, 2015 路 12 Nov 2026
- Aptus Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting for .... 路 06 Nov 2026
- Transcript for Earning Call for the Quarter and Half Year ended on September 30, 2026 路 30 Oct 2026
- Audio recording of the Earnings Call dated October 26, 2026 路 27 Oct 2026
- Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 路 23 Oct 2026
- Intimation of Earnings Call for the quarter and half year ended September 30, 2026 路 26 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... 路 21 Oct 2026
- Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company .... 路 21 Oct 2026
